Condition: Advanced Hepatocellular Carcinoma · Anti-PD1/PDL1 Antibody · Bevacizumab · Sponsor: Sun Yat-sen University
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.
This description comes directly from the study's public registry record.
Qunfang Zhou, MD · 86 19868000115 · zhouqun988509@163.com
Feng Duan, MD · 13910984586 · duanfeng@vip.sina.com
Always discuss trial participation with your own doctor first.
| Chinese PLA hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06323382